Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10383539" target="_blank" >RIV/00216208:11130/18:10383539 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/18:10383539

Result on the web

<a href="https://doi.org/10.1080/2162402X.2018.1526250" target="_blank" >https://doi.org/10.1080/2162402X.2018.1526250</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2018.1526250" target="_blank" >10.1080/2162402X.2018.1526250</a>

Result language

angličtina

Original language name

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Original language description

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

OncoImmunology [online]

ISSN

2162-402X

e-ISSN

—

Volume of the periodical

7

Issue of the periodical within the volume

12

Country of publishing house

US - UNITED STATES

Number of pages

15

Pages from-to

—

UT code for WoS article

000450462000033

EID of the result in the Scopus database

2-s2.0-85058033462